Almac to Partner with Lilly UK on Lung Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Almac Diagnostics said today that it will collaborate with Lilly UK to develop a companion diagnostic for a combination lung cancer therapy.

The companies will evaluate a predictive marker for a drug combination used in treating non-squamous, non-small cell lung cancer patients. Specifically, they will study Thymidylate Synthase as a marker for response to the Eli Lilly drug pemetrexid (Alimta) in combination with cisplatin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.